SNOWMASS, COLO. – Ankylosing spondylitis, far and away, is the most common systemic disease in North America associated with uveitis, Dr. James T. R... More »
BOSTON – Secukinumab showed enduring efficacy in ankylosing spondylitis after 52 weeks of treatment, based on data reported at the annual meeting of the American College of Rheumatology.
The...
NEW YORK – Patients with ankylosing spondylitis who used opiate analgesics were five times more likely to report depression than were those who did not, in a retrospective case-control study of 611...
NEW YORK – Consistent evidence for a substantial increase in cardiovascular events remains elusive for patients with ankylosing spondylitis who have a broad range of CV risk factors.
"We can...
NEW YORK – Late initiation of tumor necrosis factor inhibitors in patients with ankylosing spondylitis more than doubles their risk of radiographic worsening, according to a prospective study that...
NEW YORK – There appears to be progress in the effort to convince the Food and Drug Administration that nonradiologic axial spondyloarthritis is a viable disease entity that deserves to be the target...
PARIS – Patients with ankylosing spondylitis who worked at more physically-demanding jobs showed greater radiographic progression than did patients who performed more sedentary jobs in a prospective...